{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "20595477",
  "DateCompleted": {
    "Year": "2010",
    "Month": "08",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.4269/ajtmh.2010.09-0621"
    ],
    "Journal": {
      "ISSN": "1476-1645",
      "JournalIssue": {
        "Volume": "83",
        "Issue": "1",
        "PubDate": {
          "Year": "2010",
          "Month": "Jul"
        }
      },
      "Title": "The American journal of tropical medicine and hygiene",
      "ISOAbbreviation": "Am J Trop Med Hyg"
    },
    "ArticleTitle": "Intravenous ibuprofen (IV-ibuprofen) controls fever effectively in adults with acute uncomplicated Plasmodium falciparum malaria but prolongs parasitemia.",
    "Pagination": {
      "StartPage": "51",
      "EndPage": "55",
      "MedlinePgn": "51-5"
    },
    "Abstract": {
      "AbstractText": [
        "Because some febrile patients are unable to swallow or retain oral antipyretic drugs, we carried out a double-blind, placebo-controlled trial in which intravenous ibuprofen (IV-ibuprofen) was given to adults hospitalized with fever associated with acute uncomplicated falciparum malaria treated with oral artesunate plus mefloquine. Thirty patients received IV-ibuprofen 400 mg and 30 received placebo every 6 hours for 72 hours. Reduction in the area above 37.0 degrees C versus time curve was significantly greater for IV-ibuprofen than for placebo during the first 72 hours after first administration. No patients developed severe malaria; parasite clearance was delayed in the patients whose fevers were controlled by IV-ibuprofen (median 37.3 hours versus 23.7 hours in the placebo group [P = 0.0024]). This difference did not appear to be clinically important Adverse events, none considered severe, occurred equally in both groups. IV-ibuprofen was effective and well tolerated in reducing fever in febrile inpatients with malaria."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Tropical Hygiene, Department of Clinical Tropical Medicine, Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand."
          }
        ],
        "LastName": "Krudsood",
        "ForeName": "Srivicha",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Tangpukdee",
        "ForeName": "Noppadon",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Wilairatana",
        "ForeName": "Polrat",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pothipak",
        "ForeName": "Nantaporn",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Duangdee",
        "ForeName": "Chatnapa",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Warrell",
        "ForeName": "David A",
        "Initials": "DA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Looareesuwan",
        "ForeName": "Sornchai",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Randomized Controlled Trial",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Am J Trop Med Hyg",
    "NlmUniqueID": "0370507",
    "ISSNLinking": "0002-9637"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antimalarials"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Artemisinins"
    },
    {
      "RegistryNumber": "60W3249T9M",
      "NameOfSubstance": "Artesunate"
    },
    {
      "RegistryNumber": "TML814419R",
      "NameOfSubstance": "Mefloquine"
    },
    {
      "RegistryNumber": "WK2XYI10QM",
      "NameOfSubstance": "Ibuprofen"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Acute Disease"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antimalarials"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Artemisinins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Artesunate"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Ibuprofen"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Injections, Intravenous"
    },
    {
      "QualifierName": [
        "drug therapy",
        "parasitology",
        "physiopathology"
      ],
      "DescriptorName": "Malaria, Falciparum"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Mefloquine"
    },
    {
      "QualifierName": [
        "drug therapy",
        "physiopathology"
      ],
      "DescriptorName": "Parasitemia"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Plasmodium falciparum"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ],
  "CoiStatement": "Disclosure: DAW's visits to the study site were sponsored by Cumberland Pharmaceuticals."
}